Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors

Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Galler M, Schatka I, Buch F, Bluemel S, Jann H,

Keywords: Lu-177-DOTATOC, PRRT, NET, dosimetry, SPECT/CT, Quantification,

#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers

Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Lauer U

Authors: Lauer U, Berchtold S, Smirnow I, Schaller M, Fehrenbacher B,

Keywords: neuroendocrine, cancer, virotherapy, virotherapeutics, preclinical, research,

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,

#2866 Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,

Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,

#1925 SSA-, H1, H2- and Leukotriene Receptor Blockade Eliminates Handicapping Symptoms from Atypical Carcinoid Syndrome

Introduction: The patient is a female, 59 yrs , previously healthy except from mild allergic rinitis since 12 years of age and at 49 a suspected anaphylaxis after hazelnut intake.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Linder Ekberg K, Dahlén S, Wheelock C, Kolmert J, Bood J,

Keywords: PGD2,